5 ms·
>"The best approach to cancer therapy is to focus on the commonalities shared by all cancer. At the moment that means lengthening of telomeres." Do you have a
by nonbel 11y ago
>"The best approach to cancer therapy is to focus on the commonalities shared by all cancer. At the moment that means lengthening of telomeres."
Do you have a source for this? Has someone actually measured telomere elongation in a bunch of different tumor biopsies and reported detection in >90%?
- JoeAltmaier 11y agoI think that's backward. Its shortened teleomeres that are linked to cell malfunction? Elongation is the supposed cure. Or is there a syndrome where cancerous cells keep lengthening theirs? Ah I see the article mentions this. But years ago it was understood that cancerous cells originally happened because of damage from short teleomeres? That end-of-life cells would divide badly and malfunction, sometimes by reproducing endlessly. So its a matter of timing? Young people want to keep their teleomeres long; but if you get cancerous cells then you want to clip them all. Sadly, that means end-of-life for the rest of your body. But no more cancer.
- adenadel 11y agoThe simple notion is that you want long telomeres to resist aging. Cancer cells "want" long telomeres to maintain their "cellular immortality", their ability to divide indefinitely. From Wikipedia: "Telomeres are critical for maintaining genomic integrity and studies show that telomere dysfunction or shortening is commonly acquired during the process of tumor development. Short telomeres can lead to genomic instability, chromosome loss and the formation of non-reciprocal translocations; and telomeres in tumor cells and their precursor lesions are significantly shorter than surrounding normal tissue."[0] "Cancer cells require a mechanism to maintain their telomeric DNA in order to continue dividing indefinitely (immortalization). A mechanism for telomere elongation or maintenance is one of the key steps in cellular immortalization and can be used as a diagnostic marker in the clinic. Telomerase, the enzyme complex responsible for elongating telomeres through the addition of telomere repeats to the ends of chromosomes, is activated in approximately 80% of tumors."[0] It's not as simple as long vs short. 0. https://en.wikipedia.org/wiki/Telomere#Cancer https://en.wikipedia.org/wiki/Telomere#Cancer
- nonbel 11y agoInteresting. Wikipedia makes that 80% claim, citing: Aschacher; Wolf; Enzmann; Kienzl (2015). "ALINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines". Oncogene. doi:10.1038/onc.2015.65. Aschacher et al write: "In about 80% of tumour cells, telomere maintenance is controlled by telomerase (TA), a reverse transcriptase, which adds DNA repeats onto chromosomal ends."12, 22, 23, 24, 25 I checked all five references and none had anything about this 80% of tumors number. It appears to be made up.
- reasonattlm 11y agohttps://www.google.com/#q=cancer+hayflick+limit https://www.google.com/#q=cancer+hayflick+limit
- nonbel 11y agoThanks, but nothing on the first page links to actual data of the type I am looking for. It would be more efficient if someone who already knows the data source could link directly to it rather than others independently rifling through search results and citation trees to find it.
- reasonattlm 11y agoRead the Wikipedia entry on the Hayflick limit and follow its references. You are actually better off as a layperson doing the thing you are objecting you - looking through materials - as it will enable you to pick the context, which you won't if you head straight for the one line summary point. http://hmg.oxfordjournals.org/content/10/7/677.full http://hmg.oxfordjournals.org/content/10/7/677.full "Telomerase activity has been found in almost all human tumors but not in adjacent normal cells."
- nonbel 11y agoThanks. They cite Kim et al (1994) and Shay and Bacchetti (1997). Table 2 of Kim et al shows up to 38% telomerase activity in normal tissue (ie head and neck) and in only 25% of breast cancers. Similarly Shay and Bacchetti reported telomerase activity in many normal tissue samples (eg table 2 GI tract normal was 25% table 9 normal epidermis was 44%). Also, Shay and Bacchetti write: "With very few exceptions, tumor cells were assayed by the PCR-based TRAP protocol... negative samples from the few studies that used the less sensitive assay without PCR amplification of telomerase products, have been disregarded". These papers are pretty old, so I thought it would be interesting to find out what has been learned about the TRAP protocol in the time since. Today, we know those methods lead to false positives: "The original TRAP method has several drawbacks. Initially, the CX oligonucleotide, which complementarily overlaps with TS for several bp, is used in the amplification of PCR products. It results in the dimerization of primers and products that emerge due to the interaction between primers. Even when using the optimal ACX primer with the noncomplementary TS end, a background signal may emerge during the analysis of concentrated extracts from tumor tissues [14]. An additional problem is encountered when using reverse primers which completely correspond to telomeric repeats. The primers are not annealed at the matrix edges during PCR (as a result of periodicity in telomeres), and hence false signals emerge." http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347595/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347595/ It would be interesting to see more recent data on this.